Two new fluvirucin aglycones, named fluvirucinins C 1 and C 2 (1-2), have been isolated from the ethyl acetate mycelial cake extract of the fermentation broth of a marine sponge-associated actinomycete. Fluvirucinins C 1 (1) and C 2 (2) represent a new type of 14-membered macrolactam aglycon, structurally related with the common aglycon of the known fluvirucins. Their structures were elucidated on the basis of 1D and 2D NMR analyses, as well as HRESIMS experiments. The antimicrobial and cytotoxic activities of compounds 1 and 2 have been evaluated, but no significant activities found for fluvirucinins C 1 and C 2 .
Fluvirucins are a family of macrolactam glycoside compounds produced by terrestrial actinomycete strains that have shown antifungal, antiviral and anthelmintic activities [1] [2] [3] [4] [5] [6] [7] [8] [9] . Their structures are characterized by a C-2, 6 and 10 tri-methyl and/or ethyl 14-membered macrolactam ring linked to an amino sugar on C-3 or 9. Fluvirucin A 2 is the only exception, having the ethyl group on C-2 hydroxylated [1] .
Due to the demonstrated biological activities, synthetic studies on fluvirucins and their aglycones have been conducted [10] [11] [12] [13] . Their biosynthetic route has also been explored. The PKS genes for fluvirucin B aglycone biosynthesis are completely described and characterized [14] , as well as the biosynthetic gene cluster for fluvirucin B1 [15] .
Although terrestrial actinomycetes are, typically, an important source for the discovery of new drug candidates, actinobacteria isolated from marine sources have also been shown to be active producers of novel bioactive compounds [16, 17] . Spongeassociated actinomycetes seem to represent 20% of the total sponge microbial community [18] and several studies have been published showing the capacity of these sponge-associated organisms to produce organic compounds with interesting biological activities [19] [20] [21] .
From a sponge-associated actinomycete strain, isolated and cultured under laboratory conditions, we have isolated and identified two never-reported fluvirucin aglycones, fluvirucinin C 1 (1) and fluvirucinin C 2 (2) whose structures have been fully elucidated using spectroscopic and spectrometric techniques. These new fluvirucinins (the common aglycon of fluvirucins) were evaluated for their antimicrobial and cytotoxic activities, but no significant activities were found. 13 C NMR spectrum of 1 (Table 1) displayed 19 signals, which were assigned with the help of HSQC data to three methyls, eleven methylenes, three methines, and two nonprotonated carbons consisting of a ketone and an amide carbonyl. Analysis of the 1 H-1 H COSY and TOCSY spectra established four partial fragments: C-2 to C-16, C-4 to C-7 to C-18, C-9 to C-20 and C-11 to C-13 which were also supported by the analysis of HMBC NMR spectral data, as shown in Figure 2 . In addition, the HMBC correlations from H 2 -15 and H-2 to C-3 and C-1, H 2 -4 to C-3 and H 2 -13 to C-1 confirmed the locations of the ketone group at C-3 and the amide carbonyl at C-1. The HMBC correlations of H 2 -19 to C-9 and C-11 and from H 2 -7 and H 2 -9 to C-8 allowed the full structure of a C-2, 6 and 10 tri-ethyl 14-membered ring macrolactam to be established. Hence, the planar structure of 1 was determined as depicted in Figure 1 and, as a new member of the fluvirucin aglycon, the compound named fluvirucinin C 1 . Compound 2 was also isolated as an amorphous white solid, with the molecular formula C 19 H 35 NO 3 as deduced from (+)-HRESIMS measurements, indicating 3 degrees of unsaturation. The 13 C NMR spectrum of 2 (Table 1) displayed 19 signals, which were assigned with the help of HSQC and H2MBC data to three methyls, eleven methylenes, two methines, and three quaternary carbons. Compound 2 possessed the same core skeleton (C-1 to C-20) as 1. Accordingly, both 1 H and 13 C NMR data of 2 (Table 1) were very similar to those of 1, the only difference in the NMR spectra of 2 and 1 being that the methine (δC 37.3, C-10) in 1 was replaced by an oxygenated quaternary carbon (δC 74.4, C-10) in 2. Detailed analysis of 2D NMR experiments, COSY, HSQC and HMBC suggested the presence of a hydroxy group at C-10 in compound 2. The position of the hydroxy group at C-10 was determined by HMBC correlation from H 3 -20 and H 2 -19 to C-10. As compound 2 represents a new fluvirucin aglycon, it has been named fluvirucinin C 2.
On the basis of the available spectroscopic data, the relative configuration for the macrolactam ring at C-2, C-6 and C-10 of compounds 1 and 2, could not be determined but we propose that is the same as reported for A and B series of fluvirucins, based on the highly similar 1D-NMR data of the aglycon [1-3, 6, 8, 9, 22] , similar specific rotations to those described for synthetic fluvirucin aglycones [10, 13] and assuming the same fluvirucin biogenetic pathway. Both the A and B series of fluvirucins possess identical absolute configurations at C-2, C-6 and C-10 which were determined by X-ray crystallography for fluvirucin A 1 and B 1 [4, 22] .
Fluvirucinins, the common aglycon of fluvirucins, have previously been obtained by synthesis [10] [11] [12] [13] but not from natural sources. The isolation of fluvirucinins C 1 and C 2 as naturally derived secondary metabolites from a marine derived microorganism is therefore the first time that this has been reported. The antimicrobial activities of 1 (10 µg/disk) and 2 (10, 20, 30 µg/disk) were determined by disk diffusion antibiotic sensitivity test [23] against Escherichia coli (ATCC 8739), Pseudomonas aeruginosa (ATCC 9027), Staphylococcus aureus (ATCC 6538) and Candida albicans (ATCC 10231) but neither showed activity against Gram-positive, Gram-negative bacteria or fungi. A comparison of the antimicrobial activity described for fluvirucins with the results for compounds 1 and 2 suggests that the sugar moiety could be essential for antifungal in vitro activity.
Experimental
General experimental procedures: UV spectra were performed using an Agilent 8453 UV−vis spectrometer. IR spectra were obtained with a Perkin-Elmer Spectrum 100 FT-IR spectrometer with ATR sampling. NMR spectra were obtained on a Varian "Unity 500" spectrometer at 500/125 MHz ( 1 H/ 13 C) and on a Varian "Unity 400" spectrometer at 400/100 MHz ( 1 H/ 13 C). Chemical shifts were reported in ppm using residual CDCl 3 (δ 7.26 ppm for 1 H and 77.0 ppm for 13 C) as an internal reference. COSY, HSQC and HMBC experiments were performed using standard pulse sequences. Data were processed using MestReNova software. (+)ESIMS were recorded using an Agilent 1100 Series LC/MS spectrometer. High resolution mass spectroscopy (HRMS) was performed an Agilent 6230 TOF LC/MS system using the ESI-MS technique.
Bacterial isolation:
The marine strain DIL-12-02-135 was isolated from a sponge sample collected in March 2012 at a depth of 45 m in the Indian Ocean. The strain was identified as an actinobacteria based on the morphological characteristics. The colonies of the microorganism were encrusting, mate-pale yellowish and the oldest colonies showed whitish peripheral sporulation, that is typical of filamentous actinomycete bacteria, as shown in Figure S1 
Fermentation and extraction:
A seed culture was developed in two scale-up steps, firstly in 100 mL Erlenmeyer flasks containing 20 mL of seed medium and then 250 mL Erlenmeyer flasks with 50 mL of the same medium. The seed culture was grown on a medium (MIBM) containing dextrose (0.1%), soluble starch 2.4%, soy peptone 0.3%, yeast extract 0.5%, tryptone 0.5%, soya flour 0.5%, sodium chloride 0.54%, potassium chloride 0.02%, magnesium chloride 0.24%, sodium sulfate 0.75%, calcium carbonate 0.4% in tap water, and the strain cultivated for 7 days at 28ºC at 220 rpm. For production, 12.5 mL of the seed medium was transferred into 2L Erlenmeyer flasks containing 250 mL of fermentation medium (MP12) containing soy peptone 0.1%, soya flour 1.2%, dextrose Fluvirucinins C 1 and C 2 produced by a marine derived Actinomycete Natural Product Communications Vol. 12 (5) 2017 681 0.25%, malt extract 0.1%, dextrin 4 %, artificial sea water 2 % and calcium carbonate 0.8%, and the culture grown at 28°C and 220 rpm. After 12 days of cultivation, the entire culture volume (5.0 L) was centrifuged to separate the mycelial cake and other solids (464.0 g) from 4.8 L of clarified broth. The mycelial cake was homogenized with a mixture of isopropanol (0.9 L) and ethyl acetate (1.4 L). The mixture was stirred vigorously and then filtered through a pad of Celite®. The organic phase was concentrated under vacuum to give 4.6 g of cell extract.
Isolation of compounds:
The organic extract (4.6 g) was separated in seven fractions by reverse phase VFC (vacuum flash chromatography), eluting stepwise using a H 2 O/MeOH/CH 2 Cl 2 gradient (500 mL of H 2 O, 400 mL of H 2 O/MeOH 3:1, 400 mL of H 2 O/MeOH 1:1, 400 mL of H 2 O/MeOH 1:3, 2x400 mL of MeOH, 400 mL of MeOH/CH 2 Cl 2 1:1 and 500 mL of CH 2 Cl 2 ). Fractions 5 (774.5 mg) and 6 (837.9 mg) eluted with MeOH were applied to a silica gel VFC system, using a gradient elution of n-hexane-EtOAc and EtOAc-MeOH mixtures to give nine fractions (200 mL of Hex:EtOAc 8:2, 150 mL of Hex:EtOAc 7:3, 150 mL of Hex:EtOAc 1:1, 150 mL of EtOAc, 150 mL of EtOAc:MeOH 9:1, 150 mL of EtOAc:MeOH 8:2, 150 mL of EtOAc:MeOH 1:1, 150 mL of EtOAc:MeOH 3:7 and 200 mL of MeOH). Fluvirucinin C1 was found in silica gel fractions 3 (11.6 mg) and 4 (34.9 mg) eluted with Hex:EtOAc (1:1) and 100% EtOAc respectively. Fluvirucinin C2 was detected in silica gel fractions 5 (23.6 mg) and 6 (9.1 mg) eluted with EtOAc:MeOH (9:1) and EtOAc:MeOH (8:2) respectively. All fractions were further submitted to semipreparative HPLC for a final purification of 1 and 2. HPLC separation experiments were monitored at 254 and 215 nm, using an XBridge C18 column (5 µm, 10x150 mm) and a linear gradient elution of H 2 O (0.05% formic acid)/CH 3 CN (0.05% formic acid) from 50% to 80% aqueous CH 3 CN (0.05% formic acid) in 30 min at a flow of 3.5 mL/min for (1) (1.5 mg eluted at 17.4 min) and 30-75% aqueous CH 3 CN (0.05% formic acid) in 20 minutes for (2) (1.0 mg eluted at 11.7 min). Cytotoxic activity: The cytotoxic activity of compounds 1-2 was tested against A-549 human lung carcinoma cells, MDA-MB-231 human breast adenocarcinoma cells, HT-29 human colorectal carcinoma cells and PSN1 human pancreatic adenocarcinoma cells. The concentration giving 50% inhibition of cell growth (GI 50 ) was calculated according to the procedure described in the literature [24] . Cell survival was estimated using the National Cancer Institute (NCI) algorithm [25] . Dose response parameters were determined at three different concentrations of fluvirucinins C 1 and C 2 .
Fluvirucinin
Antimicrobial activity: Compounds 1 and 2 were tested for antimicrobial activity via the paper disk diffusion method [23] against three bacteria, Escherichia coli (ATCC 8739), Pseudomonas aeruginosa (ATCC 9027), Staphylococcus aureus (ATCC 6538) and one fungus, Candida albicans (ATCC 10231). Seed cultures of the target strains, were prepared by incubating the organism for 24 h at 28°C in Tryptone soya broth (TSB). Aliquots of the overnight cultures were used to inoculate Tryptone soya agar (TSA) before solidification. Sterile filter disks (6 mm diameter) were infused with 10 μL that contains 10 µg of compound 1 in methanol, and added to the plates. The plates were incubated at 28°C for 24 h, for measuring the diameters of the zones of growth inhibition around each disk. The same experiment method was used to evaluate the antifungal activity of 10, 20 and 30 µg of compound 2.
Supplementary data: 1 H, 13 C, gHSQC, gCOSY and gHMBC NMR spectra of Fluvirucinins 1 and 2. Photo of DIL-12-02-135 culture on an agar plate.
